Outcomes at 6 and 12 months
| Outcomes at 6 months . | Reduction group . | Prevention group . | ||||
|---|---|---|---|---|---|---|
| . | Amlodipine (n = 12) . | Placebo (n = 11) . | P . | Amlodipine (n = 12) . | Placebo (n = 12) . | P . |
| Change in MIC, mg/g | −0.18 (−0.95 to 0.03) | −0.06 (−0.12 to 0.12) | .16 | 0.0 (−0.05 to 0.08) | 0.05 (−0.08 to 0.10) | .73 |
| Change in MIC, % | −15.6 (−37.2 to 3.5) | −3.0 (−10.5 to 15.3) | .08 | 1.5 (−8.4 to 16.7) | 8.9 (−14.4 to 18.6) | .77 |
| Change in LIC, mg/g | −0.3 (−2.8 to 1.7) | 1.5 (−0.7 to 4.6) | .10 | 0.1 (−0.45 to 2.0) | 0.5 (−0.5 to 3.4) | .82 |
| Change in LIC, % | −4.6 (−17.3 to 17.1) | 29.2 (−7.8 to 56.5) | .046 | 3.2 (−5.8 to 22.1) | 8.1 (−7.6 to 29.8) | .91 |
| Change in SF, ng/mL | −451 (−1065 to 385) | 15 (−393 to 810) | .18 | −7 (−658 to 658) | 24 (−214 to 170) | .79 |
| Change in ejection fraction, % | −0.5 (−6.5 to 4.7) | 1.0 (−4.2 to 4.7) | .60 | 0 (−3.5 to 2.0) | 2.0 (0.18-5.8) | .21 |
| Outcomes at 6 months . | Reduction group . | Prevention group . | ||||
|---|---|---|---|---|---|---|
| . | Amlodipine (n = 12) . | Placebo (n = 11) . | P . | Amlodipine (n = 12) . | Placebo (n = 12) . | P . |
| Change in MIC, mg/g | −0.18 (−0.95 to 0.03) | −0.06 (−0.12 to 0.12) | .16 | 0.0 (−0.05 to 0.08) | 0.05 (−0.08 to 0.10) | .73 |
| Change in MIC, % | −15.6 (−37.2 to 3.5) | −3.0 (−10.5 to 15.3) | .08 | 1.5 (−8.4 to 16.7) | 8.9 (−14.4 to 18.6) | .77 |
| Change in LIC, mg/g | −0.3 (−2.8 to 1.7) | 1.5 (−0.7 to 4.6) | .10 | 0.1 (−0.45 to 2.0) | 0.5 (−0.5 to 3.4) | .82 |
| Change in LIC, % | −4.6 (−17.3 to 17.1) | 29.2 (−7.8 to 56.5) | .046 | 3.2 (−5.8 to 22.1) | 8.1 (−7.6 to 29.8) | .91 |
| Change in SF, ng/mL | −451 (−1065 to 385) | 15 (−393 to 810) | .18 | −7 (−658 to 658) | 24 (−214 to 170) | .79 |
| Change in ejection fraction, % | −0.5 (−6.5 to 4.7) | 1.0 (−4.2 to 4.7) | .60 | 0 (−3.5 to 2.0) | 2.0 (0.18-5.8) | .21 |
| Outcomes at 12 months . | Reduction group . | Prevention group . | ||||
|---|---|---|---|---|---|---|
| . | Amlodipine (n = 15) . | Placebo (n = 15) . | P . | Amlodipine (n = 15) . | Placebo (n = 14) . | P . |
| Change in MIC, mg/g | −0.26 (−1.02 to −0.01) | 0.01 (−0.13 to 0.23) | .02 | 0.04 (0-0.06) | −0.01 (−0.07 to 0.03) | .07 |
| Change in MIC, % | −21.3 (−31.9 to −1.33) | 2.2 (−15.5 to 8.5) | .06 | 8.9 (0.12-12.2) | −1.3 (−13.2 to 6.6) | .07 |
| Change in LIC, mg/g | 1.3 (−5.9 to 3.5) | 1.8 (1.2-6.0) | .16 | 1.0 (0.0-3.9) | 2.4 (−1.1 to 3.3) | .98 |
| Change in LIC, % | 23.1 (−32.2 to 45.0) | 47.8 (9.5-98.9) | .05 | 9.9 (0.7-47.8) | 27.7 (−8.3 to 42) | .95 |
| Change in SF, ng/mL | −515 (−1500 to 543) | 84 (−848 to 462) | .55 | 172 (−797 to 471) | 143 (−149 to 724) | .61 |
| Change in ejection fraction, % | 1.5 (−4.0 to 7.0) | 0 (−2.7 to 6.0) | .91 | 0 (−3.3 to 5.3) | −1.0 (−3.0 to 3.1) | .46 |
| Outcomes at 12 months . | Reduction group . | Prevention group . | ||||
|---|---|---|---|---|---|---|
| . | Amlodipine (n = 15) . | Placebo (n = 15) . | P . | Amlodipine (n = 15) . | Placebo (n = 14) . | P . |
| Change in MIC, mg/g | −0.26 (−1.02 to −0.01) | 0.01 (−0.13 to 0.23) | .02 | 0.04 (0-0.06) | −0.01 (−0.07 to 0.03) | .07 |
| Change in MIC, % | −21.3 (−31.9 to −1.33) | 2.2 (−15.5 to 8.5) | .06 | 8.9 (0.12-12.2) | −1.3 (−13.2 to 6.6) | .07 |
| Change in LIC, mg/g | 1.3 (−5.9 to 3.5) | 1.8 (1.2-6.0) | .16 | 1.0 (0.0-3.9) | 2.4 (−1.1 to 3.3) | .98 |
| Change in LIC, % | 23.1 (−32.2 to 45.0) | 47.8 (9.5-98.9) | .05 | 9.9 (0.7-47.8) | 27.7 (−8.3 to 42) | .95 |
| Change in SF, ng/mL | −515 (−1500 to 543) | 84 (−848 to 462) | .55 | 172 (−797 to 471) | 143 (−149 to 724) | .61 |
| Change in ejection fraction, % | 1.5 (−4.0 to 7.0) | 0 (−2.7 to 6.0) | .91 | 0 (−3.3 to 5.3) | −1.0 (−3.0 to 3.1) | .46 |
Values represent median (95% CI).
SF, serum ferritin.